We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00854945
First Posted: March 3, 2009
Last Update Posted: June 26, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Onconova Therapeutics, Inc.
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2014
  Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Submission: October 3, 2014
Publications:
Garcia-Manero G, Fenaux P. Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). Blood Dec 2016, 128 (22) 2011; ASH 2016.